Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases.

Cancer Sci · 2025 · PMC12580884 · PMID 40817635

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, the combination of third‐generation TKIs and chemotherapy showed a trend toward prolonged OS.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Combination therapy with first‐generation TKIs showed a lower incidence of T790M‐resistant mutations than monotherapy ( p = 0.088), although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.